XY-101

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameXY-101
Drug Alias NameXY-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear receptor ROR-gamma inverse agonists
TargetsNuclear receptor ROR-gamma
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A